The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
The experimental growth hormone receptor antibody is entering testing in people with acromegaly after earlier research in healthy volunteers. Patient efficacy and longer-term safety remain unestablished.
Cell and mouse experiments suggest a mechanism that could inform research on muscle aging. Whether targeting it improves strength or mobility in older adults remains unknown.
New sponsor-reported results extend follow-up for the oral peptide in psoriasis affecting sensitive or highly visible sites. Earlier randomized findings support efficacy, while the longer follow-up lacks a continuing placebo comparison.
A small observational study links greater receipt of plant-based groceries to improvements in diastolic blood pressure, weight and BMI. The findings support further testing, but do not establish that the program caused the changes.
A Scottish cohort study links protein-based organ ages to mortality, while several other aging measures show stronger associations. The findings clarify what biological-age tests can reveal and what remains unproven.
A randomized Phase 2 trial presented at EASD found greater weight loss and increased menstrual frequency with the investigational peptide. The findings do not establish fertility benefits or long-term disease prevention.
Published Phase 3 results show greater weight loss than placebo over 76 weeks. Different analysis assumptions produce different estimates, while gastrointestinal side effects remain a substantial limitation.
Blood-cell composition explains part of the variation in epigenetic aging measures, researchers report. Its contribution to their associations with later disease and death is considerably smaller.
New Phase 2 findings suggest the experimental antibody reduces losses of lean tissue during semaglutide treatment. Whether those changes improve strength, mobility or long-term health remains unresolved.
Researchers report different patterns of brain communication associated with normal aging and Alzheimer’s pathology. The findings could inform research into cognitive vulnerability, but do not establish a diagnostic test.
A new review brings together evidence that X and Y chromosomes influence aging through mechanisms beyond hormone levels. The findings support further research into disease vulnerability, while clinical applications remain unestablished.
Scripps researchers report a way to interfere with an immune receptor through its membrane-spanning region. The laboratory findings advance peptide design, while delivery, safety and disease benefits remain unestablished.